Key words
guideline - SonoVue - safety - pediatrics
Introduction
Ultrasound (US) is the first-line, optimal imaging technique in children, with advantages
of high diagnostic yield, a wide range of applications, bedside investigation, real-time
nature of imaging and direct interaction with the patient and parents. The use of
magnetic resonance (MR) and computed tomography (CT) imaging in children has significantly
increased, often entailing the use of general anesthesia or conscious sedation to
achieve optimal imaging quality [1]
[2]. Sedation or general anesthesia presents issues for parent and patient anxiety,
as the imaging examination is more elaborate [3]
[4]. An increased morbidity is evidenced by an incidence of hypoxemia at 2.9 % and an
examination failure rate of 7 % in children who undergo sedation for MR and CT imaging
procedures [5]
[6]. Conventional iodinated contrast agents in contrast-enhanced CT (CE-CT) and gadolinium
agents in contrast-enhanced MR (CE-MR) imaging are associated with a risk for anaphylactoid
reactions [7]
[8]
[9], and there are possible long-term adverse effects with gadolinium retention in body
tissue (skin, bone, brain, liver) following CE-MR imaging [9]
[10]
[11]. With CE-CT imaging, the radiation-associated cancer risk in children has been widely
deliberated leading to the conclusion that there is a need to reduce radiation exposure
in children [12]
[13]
[14]
[15]
[16]
[17].
Since 2002, intravenous contrast-enhanced ultrasound (CEUS) has been performed in
children, with the potential to meet indications normally necessitating CE-CT and
CE-MR examinations [18]
[19]. Intravesical use of ultrasound contrast agents (UCA) for the evaluation of vesicoureteral
reflux in children was first approved for Levovist (Schering AG, Berlin, Germany)
and approved in 2016 by the European Medicines Agency (EMEA) for SonoVue (Bracco SpA,
Milan) [20]. However, intravenous UCA application remains off label in children in European
countries [21]
[22]
[23] and is approved for intravenous use in the United States of America only for the
evaluation of focal liver lesions [24]. Off-label use (and reimbursement) of any drug remains a challenge in pediatric
practice in Europe because many drugs are not subject to randomized trials in children
and as a consequence are not specifically licensed for pediatric use [25]
[26]
[27]. The application of CEUS in children has been addressed by a European Federation
of Ultrasound in Medicine and Biology (EFSUMB) position statement discussing the status
of CEUS application in children [18].
There have been previous questionnaires and literature reviews with regard to the
application of CEUS in children but no prospective recording of data related to intravenous
CEUS application in children [19]
[23]
[28]
[29]. The “EFSUMB Pediatric Registry (EFSUMB EPR)” was created with the purpose of collecting
data related to pediatric CEUS. The primary aim is to document the technique’s current
range of deployment in European countries and potential value as an alternative to
CE-CT and CE-MR imaging and secondly, to assesses and record the safety of CEUS in
children. The potential for limiting exposure to radiation and nephrotoxic contrast
agents was also ascertained, by recording the utility of the CEUS examination. The
database was limited to the use of a single UCA, SonoVue as the sole agent licensed
across European countries for adult indications, until the recent introduction of
Sonazoid (GE Healthcare, Norway) in Norway for adult indications.
Materials and Methods
Ethics committee approval was requested and provided by the National Health Service
(NHS, United Kingdom) Health Research Authority, via the South West Central Research
Ethics Committee (European Pediatric Contrast-Enhanced Ultrasound Database 16/SW/0042
IRAS Project ID 164 664). The study was approved as a database profile, with permission
to upload anonymized data, with appropriate guardianship, and to allow access to bona
fide research requests. Funding included EFSUMB support for the database and data
analysis. The database was accessed via the EFSUMB website (http://www.efsumb-data.org/v1/login.asp). Following login and entering of credentials, anonymized cases studies could be
uploaded. Two nominees of EFSUMB provided the guardianship (CFD, PSS) of the data
collection. A sequential ID number was assigned to each patient during data entry.
No identifiable data was collected on the website. The database was secured with access
for uploading cases only. Access for research to the full database was possible with
written requests to the guardians.
The database was advertised widely within the US imaging community of Europe via the
EFSUMB website and at a number of US scientific meetings. Individuals contributed
blinded pediatric CEUS cases following a set format of information Supplementary Table 1). The collected data included: the examined organ, the clinical indication, the UCA
dose, the final diagnosis and any adverse incidents. The primary aim of the EFSUMB
EPR was to ascertain current applications of pediatric CEUS in European clinical practice.
A further aim was to gather information about any adverse events and record any safety
issues.
Analysis of the clinical data was from one time point (May 2020), and all information
entered into the database at this time point was analyzed. The safety data was evaluated
at a time point of September 2020. The drafting and publication of the report followed
the stipulation of the EFSUMB policy on guidelines and position reports [30].
Results
A total of 60 cases were excluded as being outside the scope of the database purpose:
endocavitary examinations (n = 7) and > 18 years (n = 53). A total of 1463 children
entered by 19 European centers up to May 2020 were suitable for the primary clinical
analysis, and 1676 suitable for the secondary safety analysis were entered up to September
2020 (Supplementary Table 2). All recorded intravenous CEUS examinations were performed using SonoVue (Bracco
SpA, Milan) and considered for safety analysis.
Ultrasound Contrast Agent (SonoVue) Dose
A single injection was used in 1309/1463 (89.5 %), while 154/1463 (10.5 %) required
multiple injections during a single CEUS examination.
The current recommended dosages vary and include (a) 0.1 mL of SonoVue for each year
of age or (b) standard single dose of 0.1 mL, 0.5 mL, 1 mL, 1.2 mL, 2.4 mL or 4.8 mL
of SonoVue. Some authors prefer 0.1 ml SonoVue for each year of age. The recommendation
of the FDA for the dose of SonoVue/Lumason in children is based on body weight; 0.03 mL/kg
as an intravenous injection, up to a maximum of 2.4 mL per injection [24]. A commonly used dosing scheme is 0.6 ml for children aged 0–6 years, 1.2 ml for
those between 6 and 12 and 2.4 ml for those older than 12 years.
The dosage recorded in the EFSUMB EPR varied from 0.1 to 4.8 mL, and up to three injections
in a single examination were administered. In the majority (1309/1463, 89.5 %), a
single dose achieved adequate quality of examination, resulting in a shorter time
of examination. Factors determining the required dose of the UCA included the age
and weight of the patient, organ under examination and ultrasound equipment UCA sensitivity
(e. g., manufacturer, software, transducer frequency).
The dose of SonoVue for a technically adequate diagnostic study was also assessed.
In 277/1463 (18.9 %), a dose of < 1.0 ml was administered, where the average patient
age was 4.6 years. A dose of 1–1.8 ml was used in 585/1463 (40.0 %) with an average
age of 10.2 years. In 352/1463 (24.1 %), 2.0–2.4 ml of SonoVue was given, with an
average age of 14 years. Finally, 4.8 ml of SonoVue was administered in 41/1463 (2.8 %)
with an average age of 14.2 years. The age range for all doses was 1–17 years. Data
was incomplete in 208/1463 (14.2 %). This confirms that physicians abide by dosing
recommendations but variable doses were administered based on particular requirements.
Clinical Applications
The organs examined included: liver (911/1463, 62.3 %), spleen (191/1463, 13.0 %),
kidney (147/1463, 10.0 %), gastrointestinal tract (51/1463, 3.9 %), testis (35/1463,
2.4 %) and chest (25/1463, 1.7 %). Less frequently reported uses included superficial
structures (23/1463, 1.6 %), adrenal gland (20/1463, 1.5 %), gallbladder (7/1463,
0.5 %), pancreas (11/1463, 0.8 %), urogenital pelvis (20/1463, 1.4 %), vessels (6/1463,
0.4 %) and head and neck (8/1463, 0.5 %). Overall, CEUS was regarded as useful in
1242/1463 (84.9 %) applications. Supplementary Table 3 summarizes the clinical applications.
Liver
79.6 % of liver applications were for focal liver lesion (FLL) characterization and
20.4 % for trauma assessment, similar to a questionnaire-based survey [28]. The diagnostic purpose in most cases was to confirm the benign or malignant nature
of an FLL and if benign, to further characterize the nature of the benign abnormality.
Spleen
In the spleen, 53.3 % of the cases were performed for trauma and 46.7 % were performed
for lesion characterization. The characterization of splenic focal lesions is established
in the literature, where the presence of a focal lesion, although rare, is most often
benign.
Kidney
Renal applications were performed for lesion characterization (73.6 %) and for assessment
of renal trauma (26.4 %). This included diagnosis and follow-up of complicated infection
(e. g., abscess), cystic masses and complicated cysts, renal trauma, infarction, cortical
necrosis, transplants and tumor vascularity [31]
[32]
[33].
Chest
Both inflammatory and oncologic conditions have been investigated using CEUS, with
the inflammatory conditions accounting for 67.7 % and oncologic conditions for the
remainder. Lung CEUS was mainly used to differentiate consolidated lung from cavitating
pneumonia and lung abscess formation in children [34].
Liver and kidney transplantation
The application of CEUS in children following transplantation is likely to be of equal
value compared with the adult population [35]
[36]
[37]
[38]. Issues addressed included vascular patency, areas of organ necrosis, assessment
of new focal liver or renal lesions and the assessment of post-operative complications
(e. g., fluid collections).
Adrenal gland
89.0 % of adrenal examinations were performed for lesion characterization. 11.0 %
were examined for trauma. Adrenal CEUS has been used to differentiate hemorrhage and
cystic areas from neoplasms and to characterize the enhancement pattern of tumors
in adults, but rarely in children [39]
[40].
Gastrointestinal tract
Gastrointestinal system examinations were divided between solitary lesion characterization
(47.0 %) and diffuse disease assessment (53.0 %). The investigated solitary lesions
included lymphangioma, polyps, and mesenteric fibroma. A CEUS examination was commonly
used to investigate abscesses in gastrointestinal disorders but was also used to differentiate
between active and quiescent inflammatory bowel disease and to evaluate the outcome
of therapeutic strategies [41]
[42].
Pelvis
A total of 20 cases examining pelvic components of the urogenital system were recorded.
Applications included: ovary (60.0 %) for ovarian torsion and ovarian lesion characterization,
with demonstration of lack of enhancement in simple and hemorrhagic cysts. In the
urinary bladder (40.0 %), the UCA was administered for evaluation of focal lesions
and demonstration of any vascular enhancement, distinguishing viable tissue from debris.
Testis
A total of 35 cases of testicular CEUS were included. 20.0 % were performed for the
diagnosis of spermatic cord torsion and/or segmental infarction, 8.0 % for the evaluation
of complicated inflammatory conditions (e. g., epididymo-orchitis) and 64.0 % for
focal lesion characterization. CEUS was valuable for the confident establishment of
benign nature of epidermoid cysts [43].
Head and neck
A total of eight head and neck cases were included. All were performed to characterize
a focal lesion. In three (37.5 %) cases, CEUS was not deemed diagnostically useful.
The reported abnormalities included lymphoma, abscess, and a giant cell tumor.
Safety Considerations
No side effects related to the intravenous administration of the UCA, SonoVue, were
reported in 1657/1676 (98.9 %). 19 children (1.1 %) experienced adverse reactions
(Supplementary Table 4).
In a 16-year-old girl 1/1657 (0.06 %) (Patient 14), a hyperventilation attack reported
prior to injection was considered a nocebo side effect [44]
[45]. In three patients (Patients 4, 5 and 6), mild symptoms occurred 4–8 hours after
the examination procedure but were unlikely attributable to the UCA since it is eliminated
within minutes from the body.
With the remaining 15 patients, post-injection hypersensitivity reactions were categorized
as mild (6/1657; 0.4 %), moderate (5/1657; 0.3 %), and severe (4/1657; 0.2 %) on a
clinical severity grading system. The overall reaction rate was estimated at 0.9 %
[46]. Most mild hypersensitivity reactions symptoms have been previously described in
the SonoVue/Lumason “Summary of Product Characteristic” (SPC), e. g. tachycardia,
erythema, nausea, vomiting, headache, and hypotension [47]. However, a previously unreported “stupor-like” reaction in two cases (Patients
17 and 18) was observed. In both of these cases, classified as mild hypersensitivity
reactions, a noticeable abrupt “calming down” of the patient without other evident
physiological changes was seen. In addition, a slow response to commands was observed
in the case of an older child (Patient 17).
There were five hypersensitivity reactions categorized as moderate with an onset from
50 seconds to 15 minutes and a need for drug administration (Patients 2, 7, 11, 12
and 13). The four hypersensitivity reactions graded as severe showed a rapid onset
from 43 to 180 seconds (Patients 1, 3, 9 and 10) with loss of consciousness in two
children. All severe hypersensitivity reactions were successfully treated with full
recovery. No case of death was recorded.
Discussion
The EFSUMB EPR has provided a ‘snapshot’ of the current situation in European countries
with regards to the application of CEUS in the diagnosis and management of pediatric
patients. The usefulness of the technique is demonstrated by the extensive practice
despite the “off-label” applications of intravenous UCA in pediatric patients [48]. Intravenous application of SonoVue/(Lumason is licensed for the evaluation of FLL
in the United States of America, but not in Europe [24]. This has not deterred European investigators who have investigated many organs
with CEUS and indicates that practitioners are mindful of the usefulness of CEUS examination,
which is a real-time, child-friendly, repeatable examination without issues associated
with radiation. The position of a US examination within imaging for the pediatric
patient is established and the addition of a CEUS examination further improves diagnostic
capabilities [21]
[49]. The previous literature using CEUS in children demonstrates this usefulness and
also indicates the “boldness” of many practitioners in establishing this technique
[50]
[51]
[52]
[53]
[54]
[55]
[56]
[57]
[58]
[59]
[60].
The safety of CEUS has been well documented in adult patients [61]
[62], and there have been some reports of the safety in children, assessing smaller numbers,
with a similar safety profile as that seen in adults [53]
[63]
[64]
[65]
[66]. The EFSUMB guidelines and position papers on CEUS have reviewed all available evidence
and indicated that CEUS is a safe and effective examination in adults [67]
[68]
[69]. The series of Mao et al. [66], specifically investigating pediatric patients, reports an adverse reaction rate
of 6/312 (1.92 %), compared with a reaction rate of 0.9 % in the current study.
The contraindications documented by manufacturers in adults apply to children and
include a history of known hypersensitivity to the active substance, right-to-left
cardiac shunts (the FDA has recently removed this contraindication for intravenous
use of Lumason), severe pulmonary hypertension and uncontrolled systemic hypertension
[70]. The safety profile for SonoVue in adults suggests an overall rate of adverse events
that is comparable to that of the administration of contrast media used in MR imaging
and considerably lower than that of iodinated contrast media used in CT imaging [8]
[61]
[62]
[71]. However, all precautions for the management of adverse reactions should be in place
before using a UCA in a child, and the examination is best performed in a dedicated
hospital-based department, with expertise available to manage any reactions.
The anaphylactic reaction reported in a 4-year-old boy (Supplementary Table 4, Patient 3) was investigated for allergy after the incident, revealing the child’s
sensitivity to polyethylene glycol (PEG), a bio-inert, thermoelastic linear hydrophilic
polymer with the ability to increase stability and prolong in vivo circulation time
of the liposomes. The vial of the SonoVue/Lumason in addition to the sulfur hexafluoride
gas contains PEG 4000, distearoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylglycerol
sodium (DPPG-Na) and palmitic acid. Following reconstitution, the suspension of PEGylated
sulfur hexafluoride microspheres is composed of sulfur hexafluoride gas in the core
surrounded by an outer shell monolayer of phospholipids consisting of DSPC and DPPG-Na
with palmitic acid as a stabilizer. All of these substances can be considered as a
potential trigger of the hypersensitivity reaction referred to as complement activation-related
pseudo allergy (CARPA), which is classified as a non-IgE-mediated pseudo allergy caused
by the activation of the complement system [72]
[73]
[74]. With this mechanism, complement is activated in both the classic and alternative
pathways, resulting in an increase in C3a and C5a anaphylatoxins that trigger mast
cells and basophils for a secretory response underlying hypersensitivity reactions.
Again, this emphasizes the need to perform a CEUS examination in a location that has
access to resuscitation equipment and medical expertise support for resuscitation
of the pediatric patient [18]
[69]. The results from the current patient profile from the EFSUMB EPR confirms the safety
profile of the UCA, SonoVue, in children.
Characterization of FLL in children is the most commonly reported application of pediatric
intravenous CEUS in the EFSUMB EPR. Previous studies have reported evaluation of FLL
in children, confirming the feasibility, safety and high diagnostic accuracy of CEUS
for the characterization of FLL similar to CT and MR imaging [51]
[54]
[64]
[75]. The information from the EFSUMB EPR database indicates that the investigators are
applying the adult patient pattern of CEUS findings when evaluating the characteristics
of a pediatric FLL, particularly assessing the potential for malignancy, observing
washout as the marker for malignancy. In addition, benign lesions are being assessed
based on adult dynamics of the liver enhancement phases for differentiating between
different benign FLLs [76]. Current literature pertaining to the assessment of FLLs is nearly exclusively adult-based,
and validation in the pediatric population is needed [77]
[78].
CEUS is a reliable tool in the diagnosis and follow-up of solid organ injuries in
adults and is developing into a useful imaging strategy in children [60]
[79]
[80]
[81]. Pediatric patients who sustain low to moderate energy traumatic events often require
an initial CECT to identify the site of injury, and can be followed up with targeted
CEUS at the site of solid organ injury [60]. This allows for repeated examinations without the need for CE-CT and the consequently
increased radiation dose. The better spatial and temporal resolution of the CEUS examination
is likely to identify complications such as a pseudoaneurysm more readily than CE-CT
[60]
[82]. Diagnosis and follow-up of splenic, hepatic, renal and pancreatic trauma in children
is often possible using CEUS. The recommendations for CEUS in trauma are detailed
in the EFSUMB guidelines and are as follows: (a) in hemodynamically stable patients
with isolated, low or moderate energy blunt abdominal trauma; (b) in patients with
indeterminate or normal CECT findings; (c) in the follow-up of traumatic injuries
that are managed conservatively in order to ensure resolution of the lesions or detect
any associated complications, including pseudoaneurysm formation [18]
[69]. The EFSUMB EPR database confirms that this is the accepted practice, with CEUS
becoming an established follow-up imaging technique in children.
Other applications were varied, with applications in niche areas such as the testis
and the neck used in a few children. Application in renal disease follows that in
adults, with emphasis on the appearances of solid and cystic changes. Application
in the assessment of inflammatory bowel disease was noted and may well develop into
a particularly useful technique in children, thereby avoiding life-long MR and CT
imaging [83].
There are a number of limitations to this report. Firstly, the data contribution procedure
is optional and not mandatory for all fields, meaning that in some cases the information
is not provided by the contributor, thus hindering accurate analysis of some aspects
of the dataset. Secondly, there is no detailed information regarding the exact perfusion
characteristics of lesions on CEUS. This would have made data entry more problematic
and time-consuming. In general, the interpretation and assessment of the data is rather
subjective, for example when it comes to the assessment of whether CEUS was helpful
or not. Finally, there is often no histologic confirmation, hindering robust analysis
of the diagnostic accuracy of CEUS. The strength of the database lies in the reporting
of any adverse events, as this was diligently undertaken, and the overall incidence
is likely an accurate representation in this cohort of patients and remains low. However,
it is acknowledged that much larger numbers are needed to fully establish the safety
of CEUS in children.
The present assessment and the EFSUMB EPR is important as the database documents the
safety, efficiency, and accuracy of CEUS in pediatric applications. Furthermore, the
EFSUMB EPR serves as a “think tank” where everyone can share experiences, thereby
building a body of evidence and evaluating new CEUS applications as they arise. The
EFSUMB EPR acts as a “radar” for the detection and documentation of adverse UCA reactions.
The EFSUMB EPR has strengthened the impression of a good safety profile of UCA in
children. The results of the EFSUMB EPR also give insight into the daily use of CEUS
in Europe and the probable growth in the number of practitioners performing this imaging
technique [84].
